Who are Darunavir/r's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Darunavir/Ritonavir (Prezista), PEP, Reyataz + Epzicom, Lopinavir/r, AZT+3TC+IDV+RTV, Lopinavir/ritonavir (Kaletra).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/darunavir-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Darunavir/r — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Darunavir/r (Darunavir/r) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

marketed HIV protease inhibitor HIV protease Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Darunavir/r (Darunavir/r) — Juan A. Arnaiz. Darunavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Darunavir/r TARGET	Darunavir/r	Juan A. Arnaiz	marketed	HIV protease inhibitor	HIV protease
Darunavir/Ritonavir (Prezista)	Darunavir/Ritonavir (Prezista)	Kowa Research Institute, Inc.	marketed	HIV protease inhibitor	HIV protease
PEP	PEP	Christopher J. McLeod	marketed	Protease inhibitor	HIV protease
Reyataz + Epzicom	Reyataz + Epzicom	ViiV Healthcare	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease; HIV reverse transcriptase
Lopinavir/r	Lopinavir/r	Universidade Federal do Rio de Janeiro	marketed	Protease inhibitor	HIV protease
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
Lopinavir/ritonavir (Kaletra)	Lopinavir/ritonavir (Kaletra)	Abbott	marketed	HIV protease inhibitor	HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

Bristol-Myers Squibb · 5 drugs in this class
ViiV Healthcare · 3 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Drugs for Neglected Diseases · 2 drugs in this class
Germans Trias i Pujol Hospital · 2 drugs in this class
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
DualityBio Inc. · 1 drug in this class
French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
Far East Bio-Tec Co., Ltd · 1 drug in this class
Community Research Initiative of New England · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Darunavir/r — Competitive Intelligence Brief. https://druglandscape.com/ci/darunavir-r. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab